Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|August 4, 2018
Apremilast Ameliorates Experimental Arthritis <i>via</i> Suppression of Th1 and Th17 Cells and Enhancement of CD4<sup>+</sup>Foxp3<sup>+</sup> Regulatory T Cells DifferentiationWeiqian Chen, Julie Wang, Zhenjian Xu, et al.
Cancer Research|September 10, 2009
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanismLaure Escoubet-Lozach, I-Lin Lin, Kristen Jensen-Pergakes, et al.
Rheumatology and Therapy|November 14, 2019
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic StudyPeter H Schafer, Alan J Kivitz, Jianglin Ma, et al.
Annals of the Rheumatic Diseases|August 21, 2012
Pomalidomide is effective for prevention and treatment of experimental skin fibrosisSimon Weingärtner, Pawel Zerr, Michal Tomcik, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2012
Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activityAlexander L Ruchelman, Hon-Wah Man, Weihong Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugsPeter H Schafer, Anita K Gandhi, Michelle A Loveland, et al.
Microvascular Research|September 23, 2008
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsLing Lu, Faribourz Payvandi, Lei Wu, et al.
Cancer Research|January 21, 2006
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activityLing-Hua Zhang, Lei Wu, Heather K Raymon, et al.
British Journal of Haematology|December 17, 2013
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)Anita K Gandhi, Jian Kang, Courtney G Havens, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
Pageof 5